ArticleNature2024
CDK5-cyclin B1 regulates mitotic fidelity.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- The Role of Transcriptional and Atypical Cyclin-Dependent Protein Kinases in Melanoma.Cancers · 2026Review
- CD8 T lymphocytes deploy embryonic cell cycle control mechanisms for rapid cell proliferation.EMBO reports · 2026Article
- Article
- Filippi syndrome-associated CKAP2L modulates microtubule dynamics essential for mitosis and ciliary length regulation.Journal of molecular cell biology · 2026Article
- Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways.Cell death discovery · 2026Article
- Association Between CDH1 Downregulation and Lymphocyte Cell-Cycle Dysfunction in Alzheimer's Disease and Mild Cognitive Impairment.Cellular and molecular neurobiology · 2026Article
- Tumor necrosis factor α-induced endoplasmic reticulum stress promotes airway smooth muscle cell proliferation.American journal of physiology. Lung cellular and molecular physiology · 2026Article
- Machine learning-based identification of hub genes and prognostic biomarkers in prostate cancer.Frontiers in genetics · 2026Article
- Mitotic errors as triggers of cell death and inflammation.Nature cell biology · 2026Review
- The Duality of Cdk5: A Master Regulator in Neurodevelopment and a Hijacked Oncogene in Cancer.Cells · 2025Review
- HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.Cancer science · 2025Article
- Integrated Analysis, Machine Learning, Molecular Docking and Dynamics of CDK1 Inhibitors in Epithelial Ovarian Cancer: A Multifaceted Approach Towards Targeted Therapy.International journal of molecular sciences · 2025Article
- The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation.Cell reports · 2025Article
- Targeting CDK2 and other novel cell cycle targets for breast cancer therapy.Expert opinion on therapeutic targets · 2025Review
- Therapeutic Potential of Tricyclic Pyridazinone-Based Molecules: An Overview.International journal of molecular sciences · 2025Review
- Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.Signal transduction and targeted therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Xiao-Feng Zheng *Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8769-4604
Aniruddha Sarkar *Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9393-1335
Humphrey LotanaDepartment of Chemistry and Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Aleem SyedDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7942-3900
Huy NguyenDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4424-1047
Richard G IveyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jacob J KennedyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jeffrey R WhiteakerTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bartłomiej TomasikDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5648-345X
Kaimeng HuangDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0552-209X
Feng LiDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Alan D D'AndreaDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6168-6294
Amanda G PaulovichTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-6532-6499
Kavita ShahDepartment of Chemistry and Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Alexander SpektorDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Alexander_Spektor@dfci.harvard.edu.ORCID 0000-0002-1085-3205
Dipanjan ChowdhuryDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dipanjan_Chowdhury@dfci.harvard.edu.ORCID 0000-0001-5645-3752
Funding
Proteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefitU01CA214114 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BIRRER, MICHAEL, PAULOVICH, AMANDA G · 2017 to 2021
$8.4MMOLECULAR PATHOGENESIS OF FANCONI ANEMIAR01HL052725 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI ALAN D. D'ANDREA · 1994 to 2026
$5.9MProteogenomic studies to understand mechanisms and drivers of resistance to immunotherapiesU01CA271407 · NCI · FRED HUTCHINSON CANCER CENTER · PI Diwakar Davar, AMANDA G PAULOVICH · 2022 to 2026
$5.6MA proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancerR50CA211499 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jeff Whiteaker · 2016 to 2026
$2.8MElucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53R01CA264900 · NCI · DANA-FARBER CANCER INST · PI Dipanjan Chowdhury · 2022 to 2026
$1.9MInvestigating 53BP1 'dephosphorylation' as a critical determinant of PARPR01CA208244 · NCI · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2017 to 2021
$1.9MTargeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2R01CA237660 · NCI · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2020 to 2024
$1.2MValidation of HYPE as an Actionable Target for Alzheimer's DiseaseRF1NS124779 · NINDS · PURDUE UNIVERSITY · PI SHAH, KAVITA · 2022 to 2022
$1.2MThe mechanism of DNA damage and chromothripsis from chromosome segregation errorsK08CA208008 · NCI · DANA-FARBER CANCER INST · PI SPEKTOR, ALEXANDER · 2016 to 2020
$886kNCI NIH HHS K08 CA208008NCI NIH HHS R01 CA208244NCI NIH HHS R01 CA237660NCI NIH HHS R01 CA264900NCI NIH HHS R50 CA211499NCI NIH HHS U01 CA214114NCI NIH HHS U01 CA271407NHLBI NIH HHS R01 HL052725NINDS NIH HHS RF1 NS124779
Abstract
CDK1 has been known to be the sole cyclin-dependent kinase (CDK) partner of cyclin B1 to drive mitotic progression
Indexed as
Cyclin B1Cyclin-Dependent Kinase 5MitosisMultiprotein ComplexesCDC2 Protein KinaseCoenzymesHeLa CellsHumansModels, MolecularMutationPhosphoproteinsProtein BindingProteomeReproducibility of ResultsCCNB1 protein, humanCDC2 Protein KinaseCDK1 protein, humanCDK5 protein, humanCoenzymesCyclin B1Cyclin-Dependent Kinase 5Multiprotein ComplexesPhosphoproteinsProteome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.